AstraZeneca discontinues brazikumab inflammatory bowel disease development programme

Published On 2023-06-02 08:00 GMT | Update On 2023-06-02 08:01 GMT

Cambridge: AstraZeneca has announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development programme, an anti-IL-23 monoclonal antibody, being investigated for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC).

The IBD development programme for brazikumab included the Phase IIb/III INTREPID trial in CD and the Phase II EXPEDITION trial in UC, and their respective open-label extension trials.

The decision to discontinue brazikumab’s IBD development follows a recent review of brazikumab’s development timeline and the context of a competitive landscape that has continued to evolve. The timeline was impacted by delays that could not be mitigated following global events. No safety concerns were identified for patients in these trials.

Under an agreement from 2020, AbbVie contributed to ongoing funding of the development programme, but this funding will now cease.

Brazikumab is a monoclonal antibody that binds to IL23, thus preventing its interaction with its receptor, and was in development for CD and UC.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AstraZeneca discontinues brazikumab inflammatory bowel disease development programme

Similar News

Lupin: Manufacturing Operations President Rajendra Chunodkar retires

Lupin unveils Rivaroxaban for Oral Suspension in US following USFDA approval

Bombay HC Grants Relief to Sun Pharma in Trademark Battle Over Lupride

Probe Launched Against Rajasthan Pharma Firm Over Dextromethorphan Syrup-Linked Death

Novartis Rhapsido gets USFDA nod for chronic spontaneous urticaria

MSN Lab gets CDSCO panel nod for Phase IV CT of Tofacitinib Tablets 10 mg

India's pharma exports expected to cross USD 30 billion by this year end: Dr Jitendra Singh

Meghalaya Pharmacists Await Service Rules Even After 50 Years of Statehood